6-氯咪唑[1,2-A]嘧啶 | 944906-56-3

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]嘧啶
• 中文名称: 6-氯咪唑[1,2-A]嘧啶
• 英文名称: 6-chloroimidazo[1,2-a]pyrimidine
• CAS: 944906-56-3
• 化学式: C₆H₄ClN₃
• mdl: MFCD10574899
• 分子量: 153.571
• InChiKey: RFCCGIKVKLWJRA-UHFFFAOYSA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  6-氯咪唑[1,2-A]嘧啶 在 N-碘代丁二酰亚胺 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 3-iodo-6-[2-(methoxymethyl)-4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyrimidine
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR METHODS OF USE
  [FR] COMPOSÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或病况，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或病况的方法，包括德拉维特综合征或癫痫。

  公开号：

  WO2018098500A1
• 作为产物：
  描述：

  氯乙醛 、 2-氨基-5-氯嘧啶 以 乙醇 为溶剂， 反应 4.0h， 以2.05 g的产率得到6-氯咪唑[1,2-A]嘧啶
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR METHODS OF USE
  [FR] COMPOSÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或病况，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或病况的方法，包括德拉维特综合征或癫痫。

  公开号：

  WO2018098500A1

文献信息

• Therapeutic inhibitory compounds
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US10023557B2

  公开（公告）日：2018-07-17

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

  本文提供的杂环衍生物化合物和药物组合物包含所述化合物，可用于抑制血浆卡利克林。此外，所述化合物和组合物还可用于治疗与血浆卡利克酶抑制作用有关的疾病，如血管性水肿等。
• A Novel Pyrazolopyridine with in Vivo Activity in <i>Plasmodium berghei</i>- and <i>Plasmodium falciparum</i><i>-</i>Infected Mouse Models from Structure–Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines
  作者：Claire Le Manach、Tanya Paquet、Christel Brunschwig、Mathew Njoroge、Ze Han、Diego Gonzàlez Cabrera、Sridevi Bashyam、Rajkumar Dhinakaran、Dale Taylor、Janette Reader、Mariette Botha、Alisje Churchyard、Sonja Lauterbach、Theresa L. Coetzer、Lyn-Marie Birkholtz、Stephan Meister、Elizabeth A. Winzeler、David Waterson、Michael J. Witty、Sergio Wittlin、María-Belén Jiménez-Díaz、María Santos Martínez、Santiago Ferrer、Iñigo Angulo-Barturen、Leslie J. Street、Kelly Chibale

  DOI：10.1021/acs.jmedchem.5b01605

  日期：2015.11.12

  Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure activity relationship studies around the central core of antimalarial imidazo-pyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.
• THERAPEUTIC INHIBITORY COMPOUNDS
  申请人：LifeSci Pharmaceuticals, Inc.

  公开号：US20170029406A1

  公开（公告）日：2017-02-02

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
• COMPOUNDS AND THEIR METHODS OF USE
  申请人：Praxis Precision Medicines, Inc.

  公开号：US20210188839A1

  公开（公告）日：2021-06-24

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
• [EN] THERAPEUTIC INHIBITORY COMPOUDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2017001924A1

  公开（公告）日：2017-01-05

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.